申请人:WisTa Laboratories Ltd.
公开号:US20140161731A1
公开(公告)日:2014-06-12
Described are a compound of formula (II) or (III):
The compounds are effective in the treatment of disease, including a tauopathy condition or a disease of tau protein aggregation.
描述了一种公式为(II)或(III)的化合物:这些化合物对于治疗疾病有效,包括tau蛋白聚集的tau病理病变或疾病。